Breast cancer and pregnancy: a comparative analysis of a Chilean cohort

Sánchez, César; Acevedo, Francisco; Medina, Lidia; Ibáñez, Carolina; Razmilic, Dravna; Elena Navarro, M.; Camus, Mauricio
June 2014
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
Academic Journal
Introduction: Recent reports show that pregnancy-associated breast cancer (PABC) survival is similar to that of non-pregnant young patients. We evaluate the characteristics and prognosis of PABC patients treated in our cancer centre. Patients and methods: We identified patients with invasive PABC who were treated between 1999 and May 2013 and compared their characteristics with a no PABC cohort of similar age. Results: The prevalence of PABC was 1% (n = 17). The median age was 35 years (range: 29- 42 years). The initial tumour was suspected clinically in 93% of the cases. Total mastectomy rates were higher in women with PABC (78.6% versus 40.5%, p = 0.02), and more tumours in the PABC group were triple negative, epidermal growth factor type 2 (HER2)-positive, and at advanced stages; however, these differences were not statistically significant. While estimated overall survival at ten years was higher in the non-PABC group (75.5% versus 80.5%, p = 0.043), disease-specific survival (DSS) rate at ten years was not statistically different between groups (83.9% for PABC and 75.5% for unrelated pregnancy BC, p = 0.37). Conclusions: PABC is a rare event. In our cohort, it tended to be more aggressive. Compared with a similar age cohort, the DSS was not worse.


Related Articles

  • Young breast cancer: A single center experience. Gogia, A.; Raina, V.; Deo, S. V. S.; Shukla, N. K.; Mohanti, B. K. // Indian Journal of Cancer;Oct-Dec2014, Vol. 51 Issue 4, p604 

    Background: Breast cancer in women aged less than 35 years is uncommon and accounts for 1-2% of all breast cancer in the West. There is a paucity of data on young breast cancer from India. The aim of this study was to analyze the clinical, pathological, prognostic factors and...

  • The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China. Wu, Haibo; Wang, Wei; Du, Jun; Li, Hong; Wang, Huogang; Huang, Liangliang; Xiang, Hang; Xie, Jing; Liu, Xiaoli; Li, Heng; Lin, Wenchu // Cancer Management & Research;Feb2019, Vol. 11, p1473 

    Purpose: The mutation status and prognostic value of PIK3CA in breast cancer were widely investigated, which showed significant difference among the patients from vast areas around the world. In this study, the frequency, distribution, bias, and burden of PIK3CA mutations and their relationships...

  • Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Petrelli, F.; Barni, S. // Medical Oncology;Dec2012, Vol. 29 Issue 4, p2586 

    High levels of human epidermal growth receptor 2 (HER2) expression are associated with recurrence and death in breast cancer (BC) patients. We have performed a systematic review and meta-analysis in order to evaluate the prognosis for HER2+ pT1a-bN0M0 BC patients. A search of PubMed and Embase...

  • Biomarkers characterization of circulating tumour cells in breast cancer patients.  // Breast Cancer Research;2012, Vol. 14 Issue 1, pR71 

    The article focuses on a study that analyzes the expression of epidermal growth factor receptor (EGFR) in circulating tumor cells (CTCs) of patients with breast cancer. The researchers objective was to distinguish the set of biomarkers in CTCs and correlate it with clinical-pathological...

  • Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. Rakha, E A; Tan, P H; Varga, Z; Tse, G M; Shaaban, A M; Climent, F; van Deurzen, C H M; Purnell, D; Dodwell, D; Chan, T; Ellis, I O // British Journal of Cancer;1/20/2015, Vol. 112 Issue 2, p283 

    Background:Metaplastic breast carcinoma (MBC) is a rare type of breast cancer that has basal-like characteristics and is perceived to have poorer prognosis when compared with conventional no specific type/ductal carcinomas (ductal/NST). However, current data on MBC are largely derived from small...

  • Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Guarneri, V.; Dieci, M. V.; Barbieri, E.; Piacentini, F.; Omarini, C.; Ficarra, G.; Bettelli, S.; Conte, P. F. // Annals of Oncology;Dec2013, Vol. 24 Issue 12, p2990 

    Background Emerging literature data are showing that a change in human epidermal growth factor receptor (HER2) status adversely affects breast cancer patient's prognosis. The aim of this study was to evaluate the prognostic impact of HER2 loss in patients with HER2-positive disease treated with...

  • Breast carcinoma in pregnancy and lactation: A diagnostic and therapeutic dilemma. Al-Amri, Ali M. // International Journal of Collaborative Research on Internal Medi;Jul2011, Vol. 3 Issue 7, p542 

    Objective: To study the clinical presentation, pathological features, receptors type, and reason for the delay of diagnosis of breast carcinoma during pregnancy and lactation. Patients and methods: This is retrospective study of patients with pregnancy associated breast carcinoma (PABC), treated...

  • The factors that have an impact on the development of brain metastasis in the patients with breast cancer. Dayan, Adem; Koca, Dogan; Akman, Tulay; Oztop, Ilhan; Ellidokuz, Hulya; Yilmaz, Ugur // Journal of Cancer Research & Therapeutics;Oct-Dec2012, Vol. 8 Issue 4, p542 

    Background: To evaluate the factors that have an impact on the development of brain metastasis in patients with breast cancer. Materials and Methods: Among the patients who were followed-up and treated for breast cancer between January 2000 and January 2010, the ones with brain metastasis were...

  • Selective Anti-Proliferation of HER2-Positive Breast Cancer Cells by Anthocyanins Identified by High-Throughput Screening. Liu, Weihua; Xu, Jinmei; Wu, Shaoping; Liu, Yilun; Yu, Xiaoping; Chen, Juan; Tang, Xi; Wang, Zhi; Zhu, Xiaohu; Li, Xin // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Overexpressed Human epidermal growth factor receptor 2 (HER2) drives the biology of 20% breast cancer and is a prediction of a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients. Traditional Chinese herbs/medicines have been used to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics